Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - valsartan, amlodipine besilate - film coated tablet - 10/160 milligram - angiotensin ii antagonists and calcium channel blockers

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 160 mg - valsartan and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education p

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 160 mg - 1.1 hypertension valsartan tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valsartan -

Malta - English - Medicines Authority

krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - valsartan - film-coated tablet - valsartan 40 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - valsartan - film-coated tablet - valsartan 80 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

krka dd novo mesto Šmarješka cesta 6, 8501 novo mesto, slovenia - valsartan - film-coated tablet - valsartan 160 mg - agents acting on the renin-angiotensin system